IBD patients treated with infliximab and adalimumab often lose response to the drug over time. Repeated Therapeutic Drug Monitoring (TDM) optimizes treatment to successfully maintain the therapeutic effect of the anti-TNF biologics. Quantum Blue® TDM rapid testing by BÜHLMANN delivers a tool for monitoring that offers quantitative results within minutes to adapt anti-TNF therapy without delay. Besides the benefits in clinical routine, Quantum Blue® TDM is globally used for research projects due to its reliability and ease of use.
BÜHLMANN is proud to add Quantum Blue® Anti-Infliximab (RUO) and Quantum Blue® Anti-Adalimumab (RUO) to the TDM rapid test portfolio.